Full name
MEDONLIVE SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
uses securityreCAPTCHA
72.11.Z - Research and experimental development on biotechnology
26.60.Z - Manufacture of irradiation, electromedical and electrotherapeutic equipment
32.50.Z - Manufacture of medical and dental instruments and supplies
46.46.Z - Wholesale of pharmaceutical goods
47.74.Z - Retail sale of medical and orthopaedic goods in specialised stores
47.91.Z - Retail sale via mail order houses or via Internet
63.12.Z - Web portals
71.20.B - Other technical testing and analysis
72.19.Z - Other research and experimental development on natural sciences and engineering
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Profit (loss) on sale | -35,5 | -2,7 | -6,5 | -143,8 |
Gross profit (loss) | -35,8 | -2,7 | -7,1 | -164,4 |
EBITDA | -35,8 | -2,7 | -7 | -164,3 |
Short time liabilities | 27,1 | 41,4 | 10,3 | -75,2 |
Other operating costs | 0,4 | 0 | 0,8 | -∞ |
Equity capital | 16,9 | 14,2 | 7,2 | -49,7 |
Operating profit (EBIT) | -35,8 | -2,7 | -7 | -164,3 |
Assets | 43,9 | 105,6 | 67,4 | -36,2 |
Net profit (loss) | -35,8 | -2,7 | -7,1 | -164,4 |
Cash | 5 | 28 | 19 | -32,3 |
Net income from sale | 0 | 0 | 0 | 0 |
Liabilities and provisions for liabilities | 27,1 | 91,4 | 60,3 | -34,1 |
Working assets | 43,9 | 105,6 | 67,4 | -36,2 |
Other income costs | 0 | 0 | 0,3 | -∞ |
Depreciation | 0 | 0 | 0 | 0 |
% | % | % | p.p. | |
Profitability of capital | -212,2 | -18,8 | -98,6 | -79,8 |
Equity capital to total assets | 38,4 | 13,4 | 10,6 | -2,8 |
Gross profit margin | ||||
EBITDA Margin | ||||
Days | Days | Days | Days | |
Short term commitment turnover cycle | 2 147 483 648 | 2 147 483 648 | 2 147 483 648 | 0 |
Current financial liquidity indicator | 1.6231093406677246 | 2.5506980419158936 | 6.5654377937316895 | 4 |
Net dept to EBITDA | 0.13945139944553375 | -8.230618476867676 | -4.398443222045898 | 3,8 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane